# Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

> **NCT03945162** · PHASE2 · RECRUITING · sponsor: **Theralase® Technologies Inc.** · enrollment: 90 (estimated)

## Conditions studied

- Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG

## Interventions

- **COMBINATION_PRODUCT:** Ruvidar® (TLD-1433) bladder infusion and PDT

## Key facts

- **NCT ID:** NCT03945162
- **Lead sponsor:** Theralase® Technologies Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-08-30
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03945162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03945162, "Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03945162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*